HomeAbout usProductsInvestor centreMedia centrePartneringCareers

Press releases

21/02/2008

Antisoma plc reports half-year results

London, UK: 21 February 2008 Cancer drug developer Antisoma plc (LSE: ASM; USOTC:ATSMY) announces its interim financial information for the period ended 31 December 2007.

Highlights

ASA404

  • Positive survival data from second phase II lung cancer trial
  • Encouraging interim findings from phase II prostate cancer trial
  • Broad patient population selected for phase III lung cancer trial

AS1411

  • Advanced into phase II in AML (acute myeloid leukaemia)

AS1409

  • Phase I trial started in renal cancer and melanoma (announced today)

Financial highlights

  • Six month revenues of £16.5 million (2006: £0.3 million)
  • Profit before tax of £4.1 million (2006: loss £7.5 million)
  • Cash resources at 31 December 2007 of £50.4 million (2006: £33.6 million)

Glyn Edwards, CEO of Antisoma, said: “We continue to advance our portfolio of cancer drugs, with our lead drug ASA404 about to enter phase III and the first phase II data on AS1411 expected soon. We have strengthened our financial position considerably by partnering ASA404 with Novartis, leaving us well placed to realise further value from our current pipeline and to enhance our portfolio with new drugs when opportunities arise.”

An analyst presentation is scheduled for 09:30 GMT on Thursday, February 21st, and a webcast will be available to all on Antisoma’s website at www.antisoma.com.

For live viewing of the webcast, it is recommended that viewers log on 15 minutes early in order to register and download any necessary software.

Enquiries:

Glyn Edwards Chief Executive Officer

Raymond Spencer
Chief Financial Officer

Daniel Elger
Director of Communications,
Antisoma plc
+44 (0)7909 915 068

Mark Court, Lisa Baderoon, Rebecca Skye Dietrich
Buchanan Communications
+44 (0)20 7466 5000

Brian Korb
The Trout Group
+1 212 477 9007

Except for the historical information presented, certain matters discussed in this statement are forward looking statements that are subject to a number of risks and uncertainties that could cause actual results to differ materially from results, performance or achievements expressed or implied by such statements. These risks and uncertainties may be associated with product discovery and development, including statements regarding the Group's clinical development programmes, the expected timing of clinical trials and regulatory filings. Such statements are based on management's current expectations, but actual results may differ materially.

View the full press release in PDF format (134 KB, document opens in a new window)

Delivered by Investis and link to website (opens in a new window)